Mettler-Toledo International, Inc. (MTD)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- RNA Therapysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 11/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.47% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Mettler Toledo International (MTD), Why Is It Getting Fresh Attention?
- What Makes Mettler-Toledo International (MTD) an Attractive Bet?
- 2 Profitable Stocks with Competitive Advantages and 1 Facing Headwinds
- Is Mettler-Toledo Stock Underperforming the Nasdaq?
- Research Tools & Consumables Stocks Q2 Teardown: Mettler-Toledo (NYSE:MTD) Vs The Rest
- Do Wall Street Analysts Like Mettler-Toledo Stock?
- Mettler-Toledo (MTD) Upgraded to Buy: Here's Why
- What Investors Should Know as Mettler-Toledo Insiders Sell Shares After a Strong Quarter
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Mettler-Toledo International, Inc..
Full MTD Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.